Medical Devices Stocks

The device is sold once, the business runs for years

Medical device companies are frequently grouped with pharmaceuticals, and the comparison misleads. A drug faces a patent cliff, after which generic competition can remove most of its revenue within months. A device faces nothing of the sort. It is approved on a different regulatory pathway, iterated continuously rather than reinvented, and protected less by patents than by the fact that a hospital has bought the system, trained its staff on it and built procedures around it. Revenue decays slowly here, and that difference explains most of what these businesses do.

The recurring revenue is the point. Many devices are placed or sold cheaply because the money is in what follows: the sensors a patient replaces every ten days, the disposable instruments consumed in each procedure, the service contract on the imaging system. A company's installed base is therefore an asset that generates income long after the sale, and the proportion of revenue that is recurring rather than capital tells you more than the growth rate does.

The categories behave differently. Cardiovascular devices, stents, valves, ablation systems, are the largest and most competitive segment, driven by procedure volumes and by clinical trials comparing one approach to another. Diabetes management has become a technology business, with continuous monitors and automated insulin delivery competing on algorithms and patient experience as much as on hardware. Orthopaedic implants follow demographics and elective surgery volumes. Imaging is a capital equipment business tied to hospital budgets. Surgical instruments, sterilisation and hospital supplies are the steady, unglamorous foundation.

Three forces sit above the sector. Reimbursement decides whether a device that works is a device that sells, since a payer unwilling to cover it removes the market regardless of the clinical data. Hospital capital budgets set the pace for anything expensive. And procedure volumes, which collapse during a health crisis and recover afterwards, drive the consumable revenue that most of these companies depend on.

Stocks are sorted by today's price change, strongest first. Click any column header to sort by another measure, or switch to Charts for a daily candlestick of every name. This is not a recommendation to buy or sell any security. All information is provided for educational purposes only, and past performance does not guarantee future results.